Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry

Pediatrics

Volumn 114, Issue 1, 2004, Pages 19-26

  Dietrich, Kim N ^a   Ware, James H ^b   Salganik, Mikhail ^b   Radcliffe, Jerilynn ^c   Rogan, Walter J ^d   Rhoads, George G ^e   Fay, Martha E ^b   Davoli, Cecilia T ^f   Denckla, Martha B ^f   Bornschein, Robert L ^a   Schwarz, Donald ^c   Dockery, Douglas W ^b   Adubato, Susan ^g   Jones, Robert L ^h  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e RUTGERS UNIVERSITY   (United States)

^f KENNEDY KRIEGER INSTITUTE   (United States)

^g UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Chelation therapy; Child; Clinical trials; Cognition; Environmental exposure; Lead; Succimer

Indexed keywords

LEAD; MULTIVITAMIN; PLACEBO; SUCCIMER;

ACADEMIC ACHIEVEMENT; ARTICLE; ATTENTION; BODY SURFACE; BRAIN DEVELOPMENT; CHELATION THERAPY; CHILD BEHAVIOR; CHILD DEVELOPMENT; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HAZARD; HUMAN; LANGUAGE; LEAD BLOOD LEVEL; LEAD POISONING; LEARNING; MAJOR CLINICAL STUDY; MEMORY; MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

CHELATING AGENTS; CHELATION THERAPY; CHILD; CHILD BEHAVIOR; CHILD DEVELOPMENT; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; ENVIRONMENTAL EXPOSURE; HUMANS; INFANT; INTELLIGENCE; LEAD; LEAD POISONING; NEUROPSYCHOLOGICAL TESTS; SUCCIMER;

EID: 3042711943     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.114.1.19     Document Type: Article

References (39)

1. Christian JR, Celewycz BS, Andelman SH. A three-year study of lead poisoning in Chicago. Am J Public Health. 1964;54:1241-1245
2. Chisolm JJ Jr, Harrison HE. The exposure of children to lead. Pediatrics. 1956;18:943-957
3. Perlstein MA, Attala R. Neurologic sequelae of plumbism in children. Clin Pediatr. 1966;5:292-298
4. Pirkle JL, Kaufmann RB, Brody DJ, et al. Exposure of the US population to lead, 1991-1994. Environ Health Perspect. 1998;11:745-750
5. Centers for Disease Control and Prevention. Blood lead levels in young children-United States and selected states, 1996-1999. MMWR Morb Mortal Wkly Rep. 2000;49:1133-1137
6. Lanphear BP, Dietrich KN, Berger O. Prevention of lead toxicity in US children. Ambul Pediatr. 2003;3:27-36
7. Canfield RL, Henderson CR, Cory-Slechta DA, Cox C, Jusko TA, Lanphear BP. Intellectual impairment in children with blood lead levels below 10 μg/dL. N Engl J Med. 2003;348:1517-1526
8. Nightingale SL. Succimer (DMSA) approved for severe lead poisoning. JAMA. 1991;265:1802
9. United States Centers for Disease Control and Prevention. Preventing Lead Poisoning in Young Children: A Statement by the Centers for Disease Control and Prevention, October 1991. 4th rev. Atlanta, GA: Centers for Disease Control and Prevention; 1991
10. Graziano JH, Lolacono NJ, Meyer P. Dose response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations. J Pediatr. 1988;113:751-757
11. Treatment of Lead-exposed Children Trial Group. The treatment of lead-exposed children (TLC) trial: design and recruitment for a study of the effect of oral chelation on growth and development of children. Paediatr Perinat Epidemiol. 1998;12:313-333
12. Treatment of Lead-Exposed Children (TLC) Trial Group. Safety and efficacy of succimer in toddlers with blood lead levels of 20-44 μg/dL. Pediatr Res. 2000;48:593-599
13. Rogan WJ, Dietrich KN, Ware JH, et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med. 2001;344:1421-1426
14. Liu X, Dietrich KN, Radcliffe J, et al. Do children with falling blood lead levels have improved cognition? Pediatrics. 2002;110:787-791
15. Ruff HA, Bijur PE, Markowitz M, Ma YC, Rosen JF. Declining blood lead levels and cognitive changes in moderately lead-poisoned children. JAMA. 1993;269:1641-1646
16. Bayley N. The Bayley Scales of Infant Development-II. San Antonio, TX: The Psychological Corporation; 1993
17. Wechsler D. The Wechsler Preschool and Primary Scales of Intelligence-Revised. San Antonio, TX: The Psychological Corporation; 1989
18. Korkman M, Kirk U, Kemp S. NEPSY - A Developmental Neuropsychological Assessment. San Antonio, TX: The Psychological Corporation; 1998
19. Conners CK. Conners' Rating Scales-Revised. Technical Manual. North Tonawanda, NY: Multi-Health Systems; 1997
20. Silverstein AM. Two- and four-subtest short forms of the WAIS-R: a closer look at validity and reliability. J Clin Psychol. 1985;41:95-97
21. Lidsky TI, Schneider JS. Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain. 2003;126:5-19
22. Dietrich KN. Environmental neurotoxicants and psychological development. In: Yeates KO, Ris MD, Taylor HG, eds. Pediatric Neuropsychology: Research, Theory and Practice. New York, NY: Guilford Press; 2000: 206-234
23. Wechsler D. Wechsler Intelligence Scalefor Children-III. San Antonio, TX: The Psychological Corporation; 1991
24. Conners CK. Conners' Continuous Performance Test. North Tonawanda, NY: Multi-Health Systems; 1995
25. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test-Children's Version. San Antonio, TX: The Psychological Corporation; 1994
26. Woodcock RW. Woodcock Language Proficiency Battery-Revised. Itasca, IL: Riverside Publishing; 1991
27. Reynolds CR, Kamphaus RW. Behavior Assessment System for Children. Circle Pines, MN: American Guidance Service; 1992
28. Denckla MB. Revised neurological examination for subtle signs. Psychopharm Bull. 1985;24:773-778
29. Peterson KE, Salganik M, Campbell C, et al. Effect of succimer on growth of preschool children with moderate blood lead levels. Environ Health Perspect. 2004;112:233-237
30. Dean AG, Dean JA, Colombier D, et al. Epi Info Version 6: A Word-Processing Database and Statistics Program for Public Health on IBM-Compatible Microcomputers. Atlanta, GA: Centers for Disease Control and Prevention; 1996
31. Jones MM, Basinger MA, Gale GR, Atkins LM, Smith AB, Stone A. Effect of chelate treatments on kidney, bone and brain lead levels of lead-intoxicated mice. Toxicology. 1994;89:91-100
32. Smith D, Bayer L, Strupp J. Efficacy of succimer chelation for reducing brain Pb levels in a rodent model. Environ Res. 1998;78:168-176
33. Smith DR, Woolard D, Luck ML, Laughlin NK. Succimer and the reduction of tissue lead in juvenile monkeys. Toxicol Appl Pharmacol. 2000;166:230-240
34. Cremin JD, Luck ML, Laughlin NK, Smith DR. Efficacy of succimer chelation for reducing brain lead in a primate model of human lead exposure. Toxicol Appl Pharmacol. 1999;161:283-293
35. Welsh MC, Pennington BF. Assessing frontal lobe functioning in children: views from developmental psychology. Dev Neuropsychol. 1988;4:199-230
36. Denckla MB. A theory and model of executive function: A neuropsychological perspective. In: Lyon GR, Krasnegor NA, eds. Attention, Memory, and Executive Function. Baltimore, MD: Paul H. Brookes Publishing Co; 1996:263-278
37. Anderson V. Assessing executive functions in children: biological, psychological, and developmental considerations. Neuropsychol Rehabil. 1998;8:319-349
38. United States Centers for Disease Control and Prevention. Managing Elevated Blood Lead Levels Among Young Children: Recommendations From the Advisory Committee on Childhood Lead Poisoning Prevention, March, 2002. Atlanta, GA: Centers for Disease Control and Prevention; 2002
39. Lanphear BP. The paradox of lead poisoning prevention. Science. 1998; 281:1617-1618